Literature DB >> 20840873

Handling missing data issues in clinical trials for rheumatic diseases.

Weng Kee Wong1, W J Boscardin, A E Postlethwaite, D E Furst.   

Abstract

Missing data are ubiquitous in clinical trials for rheumatic diseases, and it is important to accommodate them using appropriate statistical techniques. We review some of the basic considerations for missing data and survey a range of statistical techniques for analysis of longitudinal clinical trial data with missingness. Using clinical trial data from patients with diffuse systemic sclerosis, we show that different approaches to handling missing data can lead to different conclusions on the efficacy of the treatment. We then suggest how such discrepancies might be addressed. In particular, we emphasize that the commonly used method in rheumatic clinical trials of carrying the last observation forward to impute missing values should not be the primary analysis. We review software for analyzing different types of missing data and discuss our freely available software library for analyzing the more difficult but more realistic situation when the probability of dropout or missing data may depend on the unobserved missing value.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20840873     DOI: 10.1016/j.cct.2010.09.001

Source DB:  PubMed          Journal:  Contemp Clin Trials        ISSN: 1551-7144            Impact factor:   2.226


  6 in total

Review 1.  Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standards.

Authors:  Dinesh Khanna; Daniel E Furst; Yannick Allanore; Sangmee Bae; Vijay Bodukam; Philip J Clements; Maurizio Cutolo; Laszlo Czirjak; Christopher P Denton; Oliver Distler; Ulrich A Walker; Marco Matucci-Cerinic; Ulf Müller-Ladner; James R Seibold; Manjit Singh; Alan Tyndall
Journal:  Rheumatology (Oxford)       Date:  2014-08-13       Impact factor: 7.580

2.  Clinical and Molecular Findings after Autologous Stem Cell Transplantation or Cyclophosphamide for Scleroderma: Handling Missing Longitudinal Data.

Authors:  Lynette Keyes-Elstein; Ashley Pinckney; Ellen Goldmuntz; Beverly Welch; Jennifer M Franks; Viktor Martyanov; Tammara A Wood; Leslie Crofford; Maureen Mayes; Peter McSweeney; Richard Nash; George Georges; M E Csuka; Robert Simms; Daniel Furst; Dinesh Khanna; E William St Clair; Michael L Whitfield; Keith M Sullivan
Journal:  Arthritis Care Res (Hoboken)       Date:  2021-09-17       Impact factor: 4.794

Review 3.  Points to consider for designing trials in systemic sclerosis patients with arthritic involvement.

Authors:  Philip Clements; Yannick Allanore; Daniel E Furst; Dinesh Khanna
Journal:  Rheumatology (Oxford)       Date:  2017-09-01       Impact factor: 7.580

4.  Medical big data: promise and challenges.

Authors:  Choong Ho Lee; Hyung-Jin Yoon
Journal:  Kidney Res Clin Pract       Date:  2017-03-31

5.  Occupational therapist-led mindfulness-based stress reduction for older adults living with subjective cognitive decline or mild cognitive impairment in primary care: a feasibility randomised control trial protocol.

Authors:  Todd Tran; Catherine Donnelly; Emily Joan Nalder; Tracy Trothen; Marcia Finlayson
Journal:  BMJ Open       Date:  2020-06-23       Impact factor: 2.692

6.  Imputing missing data of function and disease activity in rheumatoid arthritis registers: what is the best technique?

Authors:  Denis Mongin; Kim Lauper; Carl Turesson; Merete Lund Hetland; Eirik Klami Kristianslund; Tore K Kvien; Maria Jose Santos; Karel Pavelka; Florenzo Iannone; Axel Finckh; Delphine Sophie Courvoisier
Journal:  RMD Open       Date:  2019-10-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.